CA2432792C - Methods for modulating tumor growth and metastasis - Google Patents

Methods for modulating tumor growth and metastasis Download PDF

Info

Publication number
CA2432792C
CA2432792C CA2432792A CA2432792A CA2432792C CA 2432792 C CA2432792 C CA 2432792C CA 2432792 A CA2432792 A CA 2432792A CA 2432792 A CA2432792 A CA 2432792A CA 2432792 C CA2432792 C CA 2432792C
Authority
CA
Canada
Prior art keywords
combretastatin
compound
tumor
administration
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2432792A
Other languages
English (en)
French (fr)
Other versions
CA2432792A1 (en
Inventor
Francis Y. Lee
Ronald Peck
David Chaplin
Ronald Pero
Klaus Edvardsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Mateon Therapeutics Inc
Original Assignee
Bristol Myers Squibb Co
Oxi Gene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Oxi Gene Inc filed Critical Bristol Myers Squibb Co
Publication of CA2432792A1 publication Critical patent/CA2432792A1/en
Application granted granted Critical
Publication of CA2432792C publication Critical patent/CA2432792C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CA2432792A 2000-12-22 2001-12-20 Methods for modulating tumor growth and metastasis Expired - Fee Related CA2432792C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25819500P 2000-12-22 2000-12-22
US60/258,195 2000-12-22
PCT/US2001/050261 WO2002056692A1 (en) 2000-12-22 2001-12-20 Methods for modulating tumor growth and metastasis

Publications (2)

Publication Number Publication Date
CA2432792A1 CA2432792A1 (en) 2002-07-25
CA2432792C true CA2432792C (en) 2012-04-03

Family

ID=22979500

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2432792A Expired - Fee Related CA2432792C (en) 2000-12-22 2001-12-20 Methods for modulating tumor growth and metastasis

Country Status (5)

Country Link
EP (1) EP1351573A4 (https=)
JP (2) JP2004523517A (https=)
AU (1) AU2002246827B2 (https=)
CA (1) CA2432792C (https=)
WO (1) WO2002056692A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2267255T3 (es) * 1998-04-03 2007-03-01 Ajinomoto Co., Inc. Agentes antitumorales.
ES2518926T3 (es) 2000-06-02 2014-11-05 Board Of Regents, The University Of Texas System Conjugados de etilendicisteína y un análogo de glucosa
HUP0302629A3 (en) 2000-10-27 2005-05-30 Aventis Pharma Sa Pharmaceutical compositions comprising a combination camptothecin and a stilbene derivative for the treatment of cancer
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
CA2432792C (en) * 2000-12-22 2012-04-03 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
US20060205771A1 (en) * 2002-09-25 2006-09-14 Mark Noble Caspase inhibitors as anticancer agents
WO2004032947A1 (en) * 2002-10-09 2004-04-22 Unibioscreen S.A. Extract with anti-tumor and anti-poisonous activity
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
EP2047858A1 (en) * 2007-10-10 2009-04-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Combination products for treating cancer
DK2219451T3 (en) 2007-11-21 2015-01-12 Oxigene Inc A method for the treatment of hematopoietic neoplasms
WO2009103076A1 (en) * 2008-02-15 2009-08-20 Oxigene, Inc. Methods and compositions for enhancing the efficacy of rtk inhibitors
FR2939665B1 (fr) 2008-12-12 2011-10-07 Sanofi Aventis Combinaison antitumorale associant l'ave8062a et le docetaxel
EP3337495A4 (en) 2015-08-18 2019-04-10 Mateon Therapeutics, Inc. USE OF VDA TO ENHANCE IMMUNOMODULATION THERAPIES AGAINST TUMORS
CN107773556B (zh) * 2016-08-26 2020-08-18 广州安好医药科技有限公司 一种具有抗肿瘤药物功效的联合用药物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996237A (en) 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
CA1338645C (en) 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
JP2002500227A (ja) 1998-01-09 2002-01-08 アリゾナ ボード オブ リーゼンツ コンブレタスタチンａ−４プロドラッグとそのトランス異性体
GB9903404D0 (en) * 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
WO2000048606A1 (en) 1999-02-18 2000-08-24 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction
CA2432792C (en) * 2000-12-22 2012-04-03 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis

Also Published As

Publication number Publication date
AU2002246827B2 (en) 2008-02-21
WO2002056692A1 (en) 2002-07-25
CA2432792A1 (en) 2002-07-25
JP2004523517A (ja) 2004-08-05
EP1351573A1 (en) 2003-10-15
JP2009102350A (ja) 2009-05-14
EP1351573A4 (en) 2007-03-28

Similar Documents

Publication Publication Date Title
CA2432792C (en) Methods for modulating tumor growth and metastasis
US20090258937A1 (en) Methods for Modulating Tumor Growth and Metastasis
AU2002246827A1 (en) Methods for modulating tumor growth and metastasis
US20090209496A1 (en) Methods and compositions for enhancing the efficacy of rtk inhibitors
EP1173187B1 (en) Combined preparations comprising morpholine anthracyclines and platinum derivatives
PL205728B1 (pl) Kombinacja zawierająca kombretastatynę i czynniki przeciwnowotworowe
AU779922B2 (en) Formulations for parenteral use of estramustine phosphate and amino acids
US20050209310A1 (en) Methods for modulating tumor growth and metastasis
JP2706371B2 (ja) 癌治療用補助剤及びそれを用いたキット
KR20090130098A (ko) 이소포스포르아미드 머스타드의 염 및 이의 동족체
AU1583201A (en) Combination chemotherapy
US6562834B2 (en) Combination comprising camptothecin and a stilbene derivative for the treatment of cancer
AU2002216029A1 (en) A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
ZA200210285B (en) Use of estramustine phosphate in the treatment of bone metastasis.
AU5063302A (en) Combination chemotherapy
AU2004248968A1 (en) Compositions comprising ZD6126 together with 5-FU, CPT-11 or 5-FU and CPT-11 having vascular damaging activity for treating e.g. colorectal cancer
US20110110940A1 (en) Methods for Enhancing the Efficacy of Vascular Disrupting Agents
US20040014729A1 (en) Use of estramustine phosphate in the treatment of bone metastasis
Sørensen et al. 218 Phase II study of bi-weekly paclitaxel (P) and cisplatin (C) for non-resectable non small-cell lung cancer (NSCLC)
Arita et al. 219 Prediction of carboplatin clearance on Japanese lung cancer patients
Zaniboni et al. 220 Taxol, ifospamide and carboplatin for NSCLC: A phase II study

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20171220